Literature DB >> 22935790

Sting of Alzheimer's failures offset by upcoming prevention trials.

Asher Mullard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22935790     DOI： 10.1038/nrd3842

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  45 in total

1.  Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example.

Authors:  Jeannie-Marie S Leoutsakos; Alexandra L Bartlett; Sarah N Forrester; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2013-08-15       Impact factor: 21.566

Review 2.  Amyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies.

Authors:  Jessica Nasica-Labouze; Phuong H Nguyen; Fabio Sterpone; Olivia Berthoumieu; Nicolae-Viorel Buchete; Sébastien Coté; Alfonso De Simone; Andrew J Doig; Peter Faller; Angel Garcia; Alessandro Laio; Mai Suan Li; Simone Melchionna; Normand Mousseau; Yuguang Mu; Anant Paravastu; Samuela Pasquali; David J Rosenman; Birgit Strodel; Bogdan Tarus; John H Viles; Tong Zhang; Chunyu Wang; Philippe Derreumaux
Journal:  Chem Rev       Date:  2015-03-19       Impact factor: 60.622

3.  Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement.

Authors:  H Hampel; S Lista
Journal:  J Nutr Health Aging       Date:  2013-01       Impact factor: 4.075

4.  Alzheimer's disease market: hope deferred.

Authors:  Zelicia Gerald; Waldemar Ockert
Journal:  Nat Rev Drug Discov       Date:  2013-01       Impact factor: 84.694

5.  Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.

Authors:  Paul S Aisen; Bruno Vellas; Harald Hampel
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

Review 6.  Prion-like propagation of protein aggregation and related therapeutic strategies.

Authors:  Sarah K Kaufman; Marc I Diamond
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

7.  The transcription factor XBP1 in memory and cognition: Implications in Alzheimer disease.

Authors:  Moustapha Cissé; Eric Duplan; Frédéric Checler
Journal:  Mol Med       Date:  2017-01-04       Impact factor: 6.354

8.  [Mild neurocognitive disorder - a disease? Against].

Authors:  L Frölich
Journal:  Nervenarzt       Date:  2014-05       Impact factor: 1.214

9.  Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.

Authors:  Alex E Roher; Chera L Maarouf; Michael Malek-Ahmadi; Jeffrey Wilson; Tyler A Kokjohn; Ian D Daugs; Charisse M Whiteside; Walter M Kalback; Mimi P Macias; Sandra A Jacobson; Marwan N Sabbagh; Bernardino Ghetti; Thomas G Beach
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 10.  Development and mechanism of γ-secretase modulators for Alzheimer's disease.

Authors:  Christina J Crump; Douglas S Johnson; Yue-Ming Li
Journal:  Biochemistry       Date:  2013-05-02       Impact factor: 3.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.